ST1968

sigma-tau i.f.r. S.p.A. · Phase 1 active Small molecule

At a glance

Generic name	ST1968
Also known as	Namitecan
Sponsor	sigma-tau i.f.r. S.p.A.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

ST1968 Intravenous (Weekly) in Solid Tumors (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ST1968 CI brief — competitive landscape report
ST1968 updates RSS · CI watch RSS
sigma-tau i.f.r. S.p.A. portfolio CI